About Trikafta
What does Trikafta do?
Helps the defective CF protein throughout the entire body
Significantly reduces time in hospital and on antibiotics
Significantly increases lung function and weight
Trikafta Facts
On average, for people taking Trikafta, lung function increased by 14.3% for those with F508del and a minimal function mutation, and 10% for those with two F508del (these people were already on Symdeko).
Through 24 weeks, pulmonary exacerbations decreased by 63%, with 78% fewer pulmonary exacerbations leading to IV antibiotics (seen in the trial for those with F508del and a minimal function mutation).
Salt chloride decreased by 41.8 mmol/L compared with placebo through 24 weeks (seen in the trial for those with F508del and a minimal function mutation).
Respiratory symptoms improved significantly, with people taking TRIKAFTA reporting an improvement of 20.2 points through 24 weeks (seen in the trial for those with F508del and a minimal function mutation).
Significant BMI increase of 1 kg/m2 on average compared with placebo at 24 weeks (seen in the trial for those with F508del and a minimal function mutation).